{"entity":{"id":"ligachem-biosciences","kind":"company","name":"LigaChem Biosciences","aka":["LigaChem Biosciences, Inc."],"tldr":"LigaChem Biosciences is a South Korea-based biotechnology company running 2 late-stage cancer trials of LCB02A and LCB84.","summary":"LigaChem Biosciences, based in Daejeon, South Korea, is a biotechnology company. LigaChem Biosciences is a biotech company focused on drug research and development, specialising in antibody-drug conjugate (ADC) therapeutics, small molecule immunotherapies and synthetic drug development. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing LCB02A and LCB84. The largest, NCT05941507 (A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumours), plans to enrol 300 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ligachembio.com"},{"label":"ClinicalTrials.gov: trials led by LigaChem Biosciences","url":"https://clinicaltrials.gov/search?lead=LigaChem%20Biosciences%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["lcb02a","lcb84"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05941507","nct07460375"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Daejeon","country":"KR","companyType":"biotech","website":"https://www.ligachembio.com","stage":"public","investors":[],"funding":[]},"route":"/companies/ligachem-biosciences/","neighbours":{"drug":[{"id":"lcb02a","kind":"drug","name":"LCB02A","route":"/drugs/lcb02a/"},{"id":"lcb84","kind":"drug","name":"LCB84","route":"/drugs/lcb84/"}],"trial":[{"id":"nct07460375","kind":"trial","name":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors","route":"/trials/nct07460375/"},{"id":"nct05941507","kind":"trial","name":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","route":"/trials/nct05941507/"}]}}